STOCK TITAN

Fulgent Genetics (FLGT) CFO reports tax withholding of vested RSU shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Fulgent Genetics CFO Paul Kim reported a routine share disposition related to tax withholding. On June 1, 2026, 2,087 shares of common stock were withheld at $18.09 per share to satisfy tax obligations triggered by the vesting of restricted stock units granted on February 25, 2025. After this withholding, Kim directly holds 362,545 shares of Fulgent Genetics common stock, indicating the transaction was a small, non-market event tied to compensation rather than an open-market sale.

Positive

  • None.

Negative

  • None.
Insider Kim Paul
Role CFO and Treasurer
Type Security Shares Price Value
Tax Withholding Common Stock 2,087 $18.09 $38K
Holdings After Transaction: Common Stock — 362,545 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Shares withheld for taxes 2,087 shares Withheld on June 1, 2026 for RSU tax obligations
Withholding price per share $18.09 per share Value used for tax-withholding disposition
Shares held after transaction 362,545 shares Direct holdings of Paul Kim following tax withholding
restricted stock units financial
"the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
tax withholding obligations financial
"The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting"
Form 4 regulatory
"which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kim Paul

(Last)(First)(Middle)
C/O FULGENT GENETICS, INC.
4399 SANTA ANITA AVENUE

(Street)
EL MONTE CALIFORNIA 91731

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Fulgent Genetics, Inc. [ FLGT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CFO and Treasurer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/01/2026F2,087(1)D$18.09362,545D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2025.
/s/ Paul Kim06/03/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Fulgent Genetics (FLGT) CFO Paul Kim report in this Form 4?

Paul Kim reported that 2,087 Fulgent Genetics shares were withheld to cover tax obligations from vesting restricted stock units. This was a compensation-related, non-market disposition rather than an open-market sale of stock.

Was the Fulgent Genetics (FLGT) CFO’s Form 4 transaction an open-market sale?

No, the transaction was not an open-market sale. Shares were withheld by the company to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units on February 25, 2025.

How many Fulgent Genetics (FLGT) shares were withheld for taxes from Paul Kim?

A total of 2,087 common shares were withheld at $18.09 per share. These shares covered tax liabilities from the vesting of restricted stock units, rather than reflecting a discretionary sale in the open market.

How many Fulgent Genetics (FLGT) shares does CFO Paul Kim hold after this Form 4?

After the tax withholding transaction, Paul Kim directly holds 362,545 Fulgent Genetics common shares. This indicates that the withheld 2,087 shares represent a small portion of his overall reported equity position.

What triggered the tax withholding transaction reported by Fulgent Genetics (FLGT) CFO?

The withholding was triggered by the vesting of restricted stock units granted to Paul Kim on February 25, 2025. When these RSUs vested, shares were withheld to satisfy the associated tax withholding obligations.